What is accretion/dilution analysis?

Accretion/dilution analysis measures whether an M&A transaction increases (accretive) or decreases (dilutive) the acquirer's earnings per share. It compares pro forma EPS after the deal to standalone EPS. A deal is accretive if pro forma EPS is higher, dilutive if lower.

Expected Time

1-2 minutes

Difficulty

Medium

Frequency

Very Common

Why Interviewers Ask This

This analysis is one of the most important outputs of M&A transaction analysis. Public company acquirers care deeply about EPS impact because it affects their stock price and shareholder perception. Understanding accretion/dilution shows you grasp how deals create or destroy value from a shareholder perspective.

How to Structure Your Answer

Define accretion and dilution, explain why it matters, walk through the key drivers, and mention how different deal structures (cash vs. stock) affect the analysis.

Key Points to Cover

Accretive = pro forma EPS > standalone EPS
Dilutive = pro forma EPS < standalone EPS
Cash deals: Compare interest cost of debt to target's earnings
Stock deals: Compare target's P/E to acquirer's P/E
Key drivers: Purchase price, synergies, financing mix, relative valuations
Rule of thumb: Acquire companies with lower P/E for accretion

Sample Answer

Accretion/dilution analysis is a key M&A output that measures whether a transaction will increase or decrease the acquirer's earnings per share.

A deal is accretive if the combined company's EPS is higher than the acquirer's standalone EPS - shareholders are better off. A deal is dilutive if pro forma EPS is lower than standalone EPS.

The mechanics depend on deal structure:

In an all-cash deal, we compare the after-tax cost of financing to the target's earnings. If the acquirer borrows at 5% and the tax rate is 25%, the after-tax cost is 3.75%. If the target's earnings yield (inverse of P/E) is higher than 3.75%, the deal is likely accretive.

In an all-stock deal, we compare P/E ratios. If the acquirer has a higher P/E multiple than the target, the deal is typically accretive. This is because the acquirer is using 'expensive' currency to buy 'cheaper' earnings. Conversely, if the acquirer has a lower P/E, issuing stock dilutes existing shareholders.

Key drivers of accretion/dilution include: - Purchase price - lower multiples paid generally mean more accretion - Synergies - cost savings and revenue synergies increase combined earnings - Financing mix - debt is often cheaper than equity cost - Transaction costs and amortization of intangibles

It's important to note that accretion/dilution shouldn't be the sole determinant of whether to do a deal. A dilutive deal might still create long-term value through strategic benefits, and an accretive deal might destroy value if the price paid exceeds intrinsic value.

Deep Dive: Worked Walkthrough

An accretion/dilution analysis tests whether a proposed acquisition will increase or decrease the acquirer's pro forma EPS in the first full year. EPS accretion is the first thing a public-company CFO asks about a deal because it's how Wall Street will grade the announcement.

**Worked example.** Acquirer: 200M shares at $50, market cap $10B, net income $500M, EPS $2.50, P/E 20x. Target: 100M shares at $30, equity value $3B, net income $150M. Acquirer offers $40/share for the target — 33% premium, $4B total. Financing: 50% stock, 50% cash. Cash from $1.5B new debt at 6% + $500M existing balance sheet cash earning 2%. Stock = 40M new shares issued. Tax rate 25%.

**Step 1: Pro forma net income.**

| Line | $M | |---|---| | Acquirer net income | 500 | | Target net income | 150 | | + After-tax synergies | 75 | | − After-tax interest on new debt | (67.5) | | − After-tax foregone cash interest | (7.5) | | − After-tax incremental D&A | (15) | | **Pro forma net income** | **635** |

**Step 2: Pro forma diluted shares.**

200M existing + 40M issued = 240M shares.

**Step 3: Pro forma EPS.**

635 / 240 = **$2.65** vs standalone $2.50 = **$0.15 of accretion, or +6.0%**.

**Breakeven synergy framework.** If pre-synergy EPS is dilutive, calculate how much in synergies you'd need to break even — common interviewer follow-up. Required after-tax synergies = (standalone EPS × pro forma shares) − (pro forma NI before synergies).

**The intuitive shortcut.** A stock deal is accretive when acquirer's P/E > target's P/E adjusted for control premium. If you trade at 20x and buy a target at 15x effective P/E, each dollar of target earnings costs fewer shares than your existing earnings produce, so EPS rises.

**Cash vs stock vs debt — directional rules.** - **Cash from balance sheet:** accretive when target's earnings yield > after-tax yield on cash (almost always). - **Debt-financed:** accretive when target's earnings yield > after-tax cost of debt. - **Stock-financed:** accretive when acquirer's P/E > target's effective P/E (target P/E divided by 1 + control premium).

**Write-ups and intangibles.** In purchase accounting, the acquirer allocates purchase price to target's assets at fair value. Intangible write-ups (customer relationships, technology) create new amortization that hits net income. Goodwill is not amortized but tested for impairment. For a control deal at 30%+ premium, write-ups can easily create $20–50M of incremental annual amortization.

**Why accretion isn't value creation.** A deal can be accretive and still destroy value if the acquirer overpaid relative to intrinsic value. Conversely, a deal can be dilutive in Year 1 and create enormous value (acquisitions of high-growth, low-current-earnings targets — accretive by Year 3). The market reaction is more correlated with strategic logic and synergies than first-year EPS impact.

Likely Follow-Up Questions (with answers)

What's the rule of thumb for stock-deal accretion?

A pure stock deal is accretive when acquirer P/E > target effective P/E (target P/E × (1 + premium)). If I trade at 20x and target at 15x, but I'm paying 30% premium, effective P/E is 19.5x. Since 20 > 19.5, marginally accretive on a pre-synergy basis. The rule explains why high-P/E acquirers do roll-up strategies — they can buy lower-P/E peers at meaningful premiums and still report accretion.

How do you calculate breakeven synergies?

Solve for synergies needed to make pro forma EPS equal standalone EPS. Required pro forma NI = standalone EPS × pro forma shares. Required after-tax synergies = required pro forma NI − pro forma NI excluding synergies. Gross up by (1 − tax) for pre-tax requirement. The CFO then asks integration leaders whether that number is realistic.

How do write-ups and goodwill affect accretion/dilution?

Under purchase accounting, the acquirer allocates purchase price to assets at fair value. Intangibles (customer relationships, technology, trade names) are amortized over useful lives — say 10 years for customer relationships — creating new expense. Goodwill is not amortized for GAAP but tested for impairment annually. A 30%+ control premium typically generates $20–50M+ per year of intangible amortization.

Why might a company pursue a dilutive deal?

Strategic value (target gives access to new market or technology). Growth profile (swap low-growth for high-growth earnings, re-rate the multiple). Defensive (block a competitor). Synergies that materialize beyond Year 1. Stock currency (if overvalued, pay with stock). Wall Street tolerates dilutive deals when the strategic narrative is compelling and management has integration credibility.

What's the difference between GAAP EPS accretion and cash EPS accretion?

GAAP EPS uses reported net income — fully burdened by amortization of acquired intangibles and deal-related restructuring. Cash EPS adds back amortization on the theory it's non-cash. The gap can be material — often the difference between 'accretion' and 'dilution' headlines. Serial acquirers (Constellation Software, Roper) emphasize cash EPS; critics call it a non-GAAP measure that masks growth costs.

What Interviewers Watch For (Red Flags)

Mistakes that flag weak candidates: (1) Forgetting after-tax adjustments — synergies, interest, D&A all flow through tax. (2) Using basic shares instead of diluted, or forgetting to add new shares issued. (3) Forgetting foregone interest income on cash used. (4) Forgetting incremental D&A from intangible write-ups. (5) Assuming Year 1 captures full run-rate synergies — realistic phasing is 30/65/100% over three years. (6) Saying 'a deal is good if it's accretive' — accretion is a Year 1 metric. (7) Treating goodwill as amortizable for GAAP. (8) Conflating GAAP EPS and cash EPS.

Common Mistakes to Avoid

Confusing accretion with value creation - they're related but not the same
Not understanding the P/E comparison for stock deals
Forgetting the impact of synergies
Not mentioning that short-term dilution might be acceptable for strategic reasons

Pro Tip

Remember: In a stock deal, the acquirer wants a higher P/E than the target. You're using expensive stock (high P/E) to buy cheap earnings (low P/E). This is often summarized as 'high P/E buys low P/E for accretion.'